Drugs / ELVN-002
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06328738 | May 2024 → Jan 2027 expected | HER2 positive breast carcinoma, colorectal cancer | Enliven Therapeutics | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05650879 | Mar 2023 → Jul 2026 overdue | HER2 positive breast carcinoma, lung cancer | Enliven Therapeutics | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ELVN-002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05650879 ↗ |
| Route | Oral | “ELVN-002 is an oral capsule.” NCT05650879 ↗ |